Login to Your Account



FDA Rejects InterMune Lung Drug; Seeks More Trial Data

By Donna Young


Wednesday, May 5, 2010
WASHINGTON - InterMune Inc. failed to win FDA approval of Esbriet (pirfenidone) as a treatment for a fatal lung disease, known as idiopathic pulmonary fibrosis (IPF), despite the strong backing of an agency panel of experts.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription